Reminder: Dixie Brands and Khiron Life Sciences to Host Investor Call
DENVER and TORONTO, Jan. 31, 2019 /CNW/ - Dixie Brands Inc. ("Dixie") (CSE: DIXI.U), (Frankfurt: 0QV), one of the cannabis industry's leading consumer packaged goods companies, and Khiron Life Sciences Corp. ("Khiron") (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), a vertically integrated medical cannabis company focused on Latin America, cordially invite investors to join them for a conference call presentation to be held later today.
Khiron president Chris Naprawa and Dixie CEO Chuck Smith will discuss details of the companies' January 30 announcement of a joint venture to bring a portfolio of cannabis-infused products to Latin America and Khiron's Kuida® cosmeceutical brand to the U.S. CBD cosmetic market.
Conference Call Details
Date: |
Thursday, January 31, 2019 |
Time: |
11:30 am EST |
Toll free: |
1-888-231-8191 |
Local/international: |
+1 647-427-7450 |
Conference ID: |
6794956 |
Webcast: |
https://event.on24.com/wcc/r/1928085/A0F4990B6941960013ABB3081840503A |
Replay: |
1-855-859-2056 or 416-849-0833 |
Passcode: 6794956 |
|
Available for 7 days following the call |
Management of both companies will deliver prepared remarks, followed by an opportunity for investors to ask questions. The call will be supported by a slide presentation that will be made available on the live webcast and on the companies' investor websites at https://investors.khiron.ca/ and http://dixieelixirs.com/ir-dashboard/. Following the call, an archive of the event can be accessed at both websites.
About Dixie Brands, Inc.
Dixie Brands Inc., through its licensed partners, has been formulating award-winning THC and CBD-infused products since 2009, and is expecting to double its manufacturing and distribution capabilities in 2019 in the U.S. as well as expand internationally, including Canada and Latin America. Dixie leads the global industry in the development, packaging design, product innovation and quality control for the commercial production of cannabis infused products. While Dixie started with a single flagship product, the Dixie Elixir (a THC-infused soda), it is now one of the industry's most recognized consumer brands, expanding to over 100 products across more than 15 different product categories representing the industry's finest edibles, tinctures, topicals and connoisseur grade extractions, as well as world-class CBD-infused wellness products and pet dietary supplements. Dixie's executive team has been instrumental in the formation of the cannabis industry for recreational and medicinal use, serving as founding members on several national regulatory and business-oriented industry organizations. To find out more about Dixie's innovative products, or about how Dixie is building the future of cannabis, visit www.dixiebrands.com.
About Khiron
Khiron Life Sciences Corp. is positioned to be the dominant integrated cannabis company in Latin America. Khiron has core operations in Colombia and is fully licensed in the country for the cultivation, production, domestic distribution, and international export of both THC (tetrahydrocannabinol) and CBD (cannabidiol) medical cannabis. In May 2018, Khiron listed on the TSX Venture Exchange, becoming one of the first Colombian-based medical cannabis companies to trade on any exchange globally. Khiron is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced executive team, and a knowledgeable Board of Directors that includes former President of Mexico, Vicente Fox.
Further information on Khiron can be found at https://investors.khiron.ca/
The CSE has neither approved nor disapproved the contents of this news release.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.
SOURCE Dixie Brands, Inc.
Contact information: For Dixie: Jeff Codispodi, Vincic Advisors, T: +1 (647) 278-9376, E: [email protected]; For Khiron: Jon Packer, Vice President, Communications, T: +1 (416) 543-9179, E: [email protected]
Share this article